AML patients in first complete remission (CR) (CR) or first complete remission with incomplete blood count recovery (CRi) after induction and consolidation chemotherapy; except young (<  years) AML patients in European LeukemiaNet favorable group; (the current trial will exclude young favorable group AML patients), patients could receive any cycle consolidation or no consolidation per the discretion by the treating physician
Completion of remission induction therapy
COHORT  PH-NEGATIVE PATIENTS ONLY: Patients must have achieved CR or CRi within  cycles of induction/re-induction with blinatumomab\r\n* NOTE: day  of post-remission = day  of the preceding cycle (+/-  days)
COHORT  PH-POSITIVE AND PH-LIKE DSMKF PATIENTS ONLY: Newly diagnosed Ph+, newly-diagnosed Ph-like DSMKF, and relapsed/refractory Ph+ patients without prior dasatinib or other nd or rd generation TKI therapy, must have achieved CR or CRi within  cycle of induction with dasatinib/prednisone, or within  cycles of re-induction with blinatumomab; relapsed/refractory Ph+ or Ph-like DSMKF patients with prior dasatinib or other nd or rd generation TKI therapy must have achieved CR or CRi within  cycles of re-induction therapy with blinatumomab\r\n* NOTE: day  of post-remission = day  of the preceding induction cycle (+/-  days), or day  of the preceding re-induction cycle (+/-  days) as applicable
leukemia refractory to ?  induction attempts,
Patients with AML refractory to primary induction chemotherapy, relapsed disease, or age >=  and not appropriate for standard cytotoxic therapy due to age, performance status, and/or adverse risk factors according to the treating physician
Acute myeloid leukemia\r\n* MRD > % at day  induction \r\n* MRD > .% after induction \r\n* FMS-like tyrosine kinase (FLT)/internal tandem duplication (ITD) with allelic ratio > . and MRD > .% at day  induction \r\n* Translocation (:), (:), (:), monosomy, monosomy , q.\r\n* M without translocation (;)\r\n* M with KMTA rearrangements, inv()(p.q.) [CBFAT-GLIS] or t(;)(p;p) [NUP-KDMA]\r\n* AML in nd or subsequent CR\r\n* Therapy related or secondary AML\r\n* Refractory anemia with excess blasts (RAEB) 
Participants must have pathologically confirmed relapsed or refractory acute myeloid leukemia following International Working Group (IWG) criteria\r\n* For subjects with relapsed AML: evidence of >= % blasts in the bone marrow or >= % blasts in peripheral blood or the development of extramedullary disease who relapse after:\r\n** Allogeneic hematopoietic stem cell transplant, or\r\n** A minimum of one cycle of standard cytotoxic chemotherapy or two cycles of any hypomethylating agent-based therapy\r\n* For subjects with refractory AML: a minimum of  prior induction regimens (example: patients who receive + followed by + would count as one induction regimen) or a minimum of two cycles of any hypomethylating agent-based therapy
PHASE I: If relapse/refractory status with no prior history of allogeneic HCT (one of the following)\r\n* nd or greater marrow relapse, with or without extramedullary disease\r\n* st marrow relapse at end of st month of re-induction with marrow having\r\n* >= .% blast by morphology and/or MPF, with or without extramedullary disease\r\n* Primary refractory as defined as having M or M marrow after  or more separate induction regimens\r\n* Subject has indication for HCT but has been deemed ineligible
Participants with leukemia must meet one of the following:\r\n* In first hematologic relapse, OR\r\n* Refractory to one or two courses of frontline induction therapy (>= % blasts in the bone marrow or peripheral blood confirmed by flow cytometric analysis)\r\n* Note: participants aged  to  years with induction failure and favorable cytogenetics (i.e., hyperdiploid or human ets variant  [ETV]-runt-related transcription factor  [RUNX]) will not be eligible for this protocol; other patients younger than  years will be eligible
AUTOLOGOUS APHERESIS: CD+ ALL with any of the following:\r\n* Minimal residual disease (MRD) >= % at end of up-front induction therapy\r\n* Hypodiploid (<  chromosomes or < . deoxyribonucleic acid [DNA] index) CD+ ALL with detectable disease at the end of up-front induction therapy \r\n* Increase in disease burden any time after the completion of up-front induction therapy\r\n* Primary refractory disease despite  cycles of an intensive chemotherapy regimen designed to induce remission\r\n* Refractory disease despite salvage therapy\r\n* st or greater relapse\r\n* Note: if patient meets CD+ ALL disease criteria, subsequent receipt of cancer directed therapy that eradicates disease does not preclude them from proceeding with this study
Patients with newly diagnosed, previously untreated B-lineage ALL, or having achieved complete remission (CR) with one course of induction chemotherapy
If relapse/refractory status with no prior history of allogeneic HCT (one of the following)\r\n* nd or greater marrow relapse, with or without extramedullary disease\r\n* st marrow relapse at end of st month of re-induction with marrow having >= .% blast by morphology and/or MPF\r\n* Primary refractory as defined as having > % blasts by multi-parameter flow after  or more separate induction regimens\r\n* Subject has indication for HCT but has been deemed ineligible, inclusive of persistent MRD
Patients must have a history of tumor progression or relapse or failure to achieve complete response following standard high-dose induction chemotherapy
Inclusion Criteria:\n\n        AML confirmed subjects aged ?  years who have achieved complete remission (CR or CRi)\n        after induction/consolidation Ara-C based therapy, that have MRD positive status and are\n        not planned for stem cell transplantation.\n\n        Exclusion Criteria:\n\n        Subjects diagnosed with acute promyelocytic leukemia or with extramedullary AML or subjects\n        who have achieved CR or CRi following treatment for AML. Subjects who have received\n        treatment with hypomethylating agents.
Diagnosis of acute myeloid leukemia (AML) and meets one of the following disease criteria:\r\n* Primary induction failure:\r\n** De Novo AML: No CR after ,  or  induction attempts with high dose chemotherapy\r\n** Secondary AML (from myelodysplastic syndrome [MDS] or treatment related): No CR after ,  or  cycles of high dose chemotherapy\r\n* Relapsed:\r\n** Not in CR after  or  cycles of standard re-induction therapy\r\n*** For patients >  years of age, the minimum of  cycle of standard chemotherapy is not required
Diagnosis of acute myeloid leukemia (AML) and meets one of the following disease criteria:\r\n* Primary induction failure:\r\n** De novo - no CR after  or more induction attempts with high dose chemotherapy\r\n** Secondary AML (from myelodysplastic syndrome [MDS] or treatment related): no CR after  or more cycles of high dose chemotherapy\r\n** Note: hypomethylating agents such as azacitidine will count as induction failure\r\n* Relapsed: not in CR after  or more cycles of standard re-induction therapy - patients >  years of age, the  cycle of standard chemotherapy is not required\r\n* Relapsed >  months after transplant: no re-induction required and no more than  re-induction cycle is allowed
Patients must be either refractory to or relapsed after only induction therapy; patients who do not achieve CR after induction therapy are considered primary refractory and are allowed to enter study
Patients with newly diagnosed, previously untreated B-lineage ALL or lymphoblastic lymphoma, or having achieved complete remission (CR) with one course of induction chemotherapy; patients who require steroids, cytarabine (ara-c) or hydrea to manage disease symptoms prior to finalization of diagnosis and treatment plan are allowed and eligible
Refractory AML without complete remission (CR) after  or more cycles of induction therapy (primary induction failure), or AML relapsed after obtaining a CR and failed one cycle of re-induction therapy; standard dose -day decitabine ( mg/m^ daily IV x  days) or -day azacitidine (- mg/m^ daily SC/IV x  days) will be considered as one cycle of induction therapy
Relapsed or refractory high-grade myeloid neoplasms, defined as having a blast count of >= % blasts at initial diagnosis; examples include excess blasts (EB)-, with >= % blasts at initial diagnosis, acute myeloid leukemia (AML) or chronic myelomonocytic leukemia (CMML-); standard definitions of relapse will apply (i.e., characterized by >= % abnormal blasts as assessed by multiparameter flow cytometry or morphologic examination; peripheral blood blasts; or extramedullary granulocytic sarcoma, per European LeukemiaNet [ELN]  guidelines); bone marrow aspirate/biopsy will be accepted if performed outside University of Washington/Fred Hutchinson Cancer Research Center (UW/FHCRC); determination of disease status should occur within  days of signing informed consent\r\n* R/R high-grade myeloid neoplasm following intensive induction chemotherapy; relapsed high-grade myeloid neoplasm: patients will be classified as relapsed if they have >= % blasts after being in a complete remission (CR) following treatment for high-grade myeloid neoplasm; refractory high-grade myeloid neoplasm: patients may be classified as refractory if they have received at least one prior cycle of induction chemotherapy, whether with cladribine cytarabine mitoxantrone (GCLAM) or another regimen\r\n** Patients may have received up to two courses of intensive induction chemotherapy during initial treatment prior to enrollment on this protocol; for example, patients who have received two courses of granulocyte colony stimulating factor (G-CSF) GCLAM (or similar) chemotherapy, with most recent high-dose cytarabine-containing chemotherapy >  months ago and CR lasting >  months, will be eligible for this protocol; regimens similar to GCLAM would include cytarabine at doses of g/m^ for at least  doses; examples of regimens similar to GCLAM would be GCLA, fludarabine cytarabine granulocyte (FLAG), and FLAG-idarubicin (ida); however, patients who received more than two courses of GCLAM (or similar) chemotherapy, or patients who received two courses of GCLAM and had CR lasting <  months, would not be eligible\r\n* R/R high-grade myeloid neoplasm following less intensive induction chemotherapy. Patients who have received at least three cycles of treatment with a hypomethylating agent (HMA; such as azacitidine or decitabine) and still have >= % blasts will be eligible for the study (they will be considered refractory); similarly, patients who have received three or more cycles of HMA therapy who have had a response (e.g., achieving CR with < % blasts), but who then progress using standard definitions of relapse, will also be eligible (they will be considered relapsed)
Very high risk pediatric patients with ALL: Patients <  years are also considered high risk CR if they had M or M marrow at day  from the initiation of induction or M marrow at the end of induction; they are eligible once they achieved a complete remission
Patients with diagnosis of AML, judged primary refractory after up to  courses of AML induction with therapy (> % blasts on day  [+/- days] bone marrow aspirate and/or biopsy from the beginning of induction chemotherapy, up to  days)
Recipients with acute lymphoblastic leukemia (ALL) in CR must have one of the following:\r\n* Adverse cytogenetics defined as translocations involving t(;), t(;), t(;), q, t(;) or bcr-abl rearrangement or complex cytogenetic abnormalities\r\n* Presence of minimal residual disease using multicolor flow cytometry or other analytic technique after primary induction chemotherapy\r\n* Primary induction failure, defined as failure to achieve CR with primary induction chemotherapy
Prior treatment (one of the following scenarios):\r\n* Primary refractory: for newly diagnosed AML, patients must have achieved two consecutive induction attempts without achieving complete remission\r\n* Relapsed/refractory: for patients initially in complete remission whose AML relapses >  months after preceding remission, one re-induction must be attempted to be eligible\r\n* Relapsed/untreated: for AML patients with early relapse, in whom the preceding remission is shorter than  months duration, no re-induction regimen is necessary to be eligible
Patients in their FIRST CR or CRi may be eligible for enrollment only if they have a high risk feature, including, but not limited to: adverse karyotype, fms-related tyrosine kinase  (FLT) mutation, history of antecedent hematologic disorder (AHD), presence of dysplasia in the bone marrow, therapy-related AML, history of requiring more than  cycle of intensive induction chemotherapy to achieve first remission, or presence of persistent minimal residual disease (detected by cytogenetics, molecular markers, or flow cytometry) at any point after initial induction cycle; patients aged >=  years with AML who have achieved a SECOND CR or CRi within  months of enrollment and are not immediately candidates for allogeneic stem cell transplant are also eligible
Relapsed or refractory AML as defined by one of the following criteria:\r\n* First relapse within  months after date of first complete response (CR) or complete response with incomplete bone marrow recovery (CRi)\r\n* Persistent AML documented by bone marrow biopsy at least  days after day  of the first induction cycle of cytotoxic chemotherapy\r\n* Hypercellular bone marrow with greater than % cellularity and % blasts at least  days after first induction cycle day 
More than  cycles of prior induction therapy for AML
DIAGNOSIS REQUIREMENT FOR PHASE I PATIENTS: Refractory AML without complete remission (CR) after induction therapy (primary induction failure) or relapsed AML after obtaining a CR OR
PHASE II ONLY: More than one course of salvage chemotherapy for primary induction failure or AML relapsing after first complete remission (CR)
Cohort B: newly diagnosed AML, failed to achieve complete remission (CR) with single standard induction chemotherapy (chemo)
Be in first relapse (within  months of CR) or have primary refractory AML (refractory to initial induction therapy using  or  cycles of intensive anthracycline/cytarabine  etoposide or cladribine induction) or have newly diagnosed high-risk AML as defined in this protocol.
CR or PR required; remission status will be assessed at the completion of induction chemotherapy and prior to enrollment on protocol
Up to one cycle of prior induction therapy will be permitted to include patients in whom presence of \good-risk\ cytogenetics was initially missed; if the patient is in remission from induction therapy, he/she will receive post-remission therapy; if the patient is not in remission then he/she will receive induction therapy
Previously untreated T cell ALL including T cell lymphoblastic lymphoma; failure to one induction course of chemotherapy are eligible; patients in CR after =<  courses are also eligible
Very high risk pediatric patients with ALL; patients <  years are also considered high risk CR if they had M or M marrow at day  from the initiation of induction or M marrow at the end of induction; they are eligible once they achieved a complete remission
B-cell cohort: Stage ; ALL in second or greater relapse or refractory to  prior induction regimens with greater than or equal to (>=)  percent (%) blasts in the bone marrow and aged  to less than (<)  years. Stage ; ALL in second or greater relapse or refractory to  prior induction regimens with (>=) % blasts in the bone marrow and aged  to  years. LL in second or greater relapse or refractory to  prior induction regimens and biopsy proven and with evidence of measurable disease by radiologic criteria and aged  to  years.
T-cell cohort: Stage ; ALL in first relapse or refractory to  prior induction/consolidation regimen with (>=) % blasts in the bone marrow and aged  to < years. Stage ; ALL in first relapse or refractory to  prior induction/consolidation regimen with (>=) % blasts in the bone marrow and aged  to  years. LL in first relapse or refractory to  prior induction/consolidation regimen biopsy proven and with evidence of measurable disease by radiologic criteria and aged  to  years
Very high risk pediatric patients with ALL: patients <  years are also considered high risk CR if they had M or M marrow at day  from the initiation of induction or M marrow at the end of induction; they are eligible once they achieve a complete remission
Inclusion Criteria:\n\n        .. Inclusion Criteria for the Biology (KIRDL Polymorphisms/ALL MRD), Comparative\n        Outcomes, and Cost Effectiveness Trial\n\n          . Any patient with ALL, AML, or MDS who is deemed eligible for and undergoes HCT at\n             participating centers who provides consent for the KIRDL polymorphisms, comparative\n             outcomes and cost-effectiveness portion of the trial.\n\n          . Any ALL patient undergoing allogeneic HCT at participating centers is eligible for the\n             ALL deep sequence MRD portion of the trial.\n\n          . Patients ineligible for the KIR-favorable haploidentical phase II trial who require\n             T-cell depletion may be treated using TCR ??+CD+/CD+ cell depletion. These patients\n             will be followed descriptively on this portion of the trial. Preparative regimen will\n             be at the discretion of the transplant center, but the options associated with this\n             protocol are recommended.\n\n        .. Inclusion Criteria for the KIR-favorable Haploidentical Phase II trial:\n\n          . Age <  years\n\n          . Disease and disease status:\n\n               -  ALL high-risk in first remission (<% blasts by morphology pre-transplant)\n                  meeting criteria for transplant. Example CR indications: induction failure (>%\n                  blasts by morphology on post-induction BM), minimal residual disease greater than\n                  or equal to % marrow blasts by morphology after induction, minimal residual\n                  disease by flow cytometry >.% after consolidation, hypodiploidy (<\n                  chromosomes), persistent or recurrent cytogenetic or molecular evidence of\n                  disease during therapy requiring additional therapy after induction to achieve\n                  remission (e.g. persistent molecular BCR-ABL positivity).\n\n               -  ALL in second remission: B-cell; early (less than or equal to  months from\n                  initiation of therapy) BM relapse, late BM relapse with MRD >.% by flow\n                  cytometry after first induction therapy; T-cell or Ph+ with BM relapse at any\n                  time; very early (less than  months from initiation of therapy) isolated\n                  extramedullary relapse (T or B-cell)\n\n               -  Myelodysplastic syndrome (MDS): Any  WHO classification subtype (Appendix I).\n                  RAEB- patients may proceed directly to transplant, but may also receive\n                  induction chemotherapy before transplant. Patients with ?% morphologic marrow\n                  blasts will require induction therapy to reduce morphologic marrow blasts below\n                  % before transplant.\n\n               -  High-risk AML defined as monosomy , del q, monosomy , M, M, t(;),\n                  FLT-ITD, or patients who have greater than or equal to % blasts by morphology\n                  after induction, or who do not achieve CR after  courses of therapy. Also,\n                  patients with ? .% MRD or evidence of progressive extramedullary disease after\n                  induction chemotherapy.\n\n               -  AML in second or subsequent morphologic remission.\n\n          . Has not received a prior allogeneic hematopoietic stem cell transplant.\n\n          . Does not have a suitable HLA-matched sibling donor available for stem cell donation.\n\n          . Does not have a suitable matched or single antigen mismatched related or unrelated\n             donor available at any time (noted by search), or it is in the patient's best interest\n             as judged by the attending to move forward with stem cell transplantation rather than\n             wait for an unrelated donor to become available (refer to subsection .. for further\n             details).\n\n          . Has a suitable HLA KIR favorable haploidentical matched family member available for\n             stem cell donation.\n\n          . Karnofsky Index or Lansky Play-Performance Scale ?  % on pre-transplant evaluation.\n             Karnofsky scores must be used for patients >  years of age and Lansky scores for\n             patients <  years of age.\n\n          . Able to give informed consent if >  years, or with a legal guardian capable of\n             giving informed consent if <  years.\n\n          . Adequate organ function (within  weeks of initiation of preparative regimen), defined\n             as:\n\n               -  Pulmonary: FEV, FVC, and corrected DLCO must all be ? % of predicted by\n                  pulmonary function tests (PFTs). For children who are unable to perform for PFTs\n                  due to age, the criteria are: no evidence of dyspnea at rest and no need for\n                  supplemental oxygen.\n\n               -  Renal: Creatinine clearance or radioisotope GFR   mL/min/. m or a serum\n                  creatinine based on age/gender as follows:\n\n        Age Maximum Serum Creatinine (mg/dL) Male Female  to <  years . .  to <  years .\n        .  to <  years    to <  years . .  to <  years . .\n\n        ?  years . . The threshold creatinine values in this Table were derived from the\n        Schwartz formula for estimating GFR utilizing child length and stature data published by\n        the CDC.\n\n          -  Cardiac: Shortening fraction of ? % by echocardiogram or radionuclide scan (MUGA) or\n             ejection fraction of ? % by echocardiogram or radionuclide scan (MUGA), choice of\n             test according to local standard of care.\n\n          -  Hepatic: \\SGOT (AST) or SGPT (ALT) <  x upper limit of normal (ULN) for age.\n             Conjugated bilirubin < . mg/dL, unless attributable to Gilbert's Syndrome.\n\n        Exclusion Criteria:\n\n          . Pregnant or lactating females are ineligible as many of the medications used in this\n             protocol could be harmful to unborn children and infants.\n\n          . Patients with HIV or uncontrolled fungal, bacterial or viral infections are excluded.\n             Patients with history of fungal disease during induction therapy may proceed if they\n             have a significant response to antifungal therapy with no or minimal evidence of\n             disease remaining by CT evaluation.\n\n          . Patients with active CNS leukemia or any other active site of extramedullary disease\n             at the time of enrollment are not permitted. Note: Those with prior history of CNS or\n             extramedullary disease, but with no active disease at the time of pre-transplant\n             workup, are eligible.\n\n          . Patients with genetic disorders (generally marrow failure syndromes) prone to\n             secondary AML/ALL with known poor outcome are not eligible (Fanconi Anemia, Kostmann\n             Syndrome, Dyskeratosis Congenita, etc).
In CR or complete remission with incomplete blood count recovery (CRi) after - induction chemotherapy documented by a bone marrow examination done within  weeks of starting cytarabine in this protocol
Must have achieved CR/CRi with less than  induction regimens that contain cytarabine and anthracycline
Patient with and without Down syndrome are eligible and must have one of the following:\r\n* Second or greater relapse;\r\n* Primary refractory disease with at least  prior induction attempts;\r\n* First relapse refractory to at least one prior re-induction attempt\r\n* Any relapse after HSCT\r\n* First relapse with no prior re-induction attempt in setting of Down syndrome\r\n* Note: Patients with Down syndrome are eligible with any disease status including first relapse with no prior re-induction attempt; patients without Down syndrome are NOT eligible if in first relapse with no prior re-induction attempt
Patients must have histologic evidence of high risk acute myeloid leukemia defined as one of the following:\r\n* Non-M AML refractory to standard primary induction therapy \r\n* Non-M AML relapsed after (i) any standard induction therapy (ii) any number of standard or experimental salvage therapies\r\n* Newly diagnosed non-M AML not eligible for intensive induction chemotherapy
To be eligible for the dose-finding phase: (the dose-finding phase completed in /) \r\n* Relapsed patients\r\n** Patients must be in first relapse, and\r\n** Patients must not have received prior re-induction therapy\r\n* Refractory patients\r\n** Patients must not have received more than one attempt at remission induction, which may consist of up to two different therapy courses; Children Oncology Group (COG) AAML de novo therapy including induction I and induction II is an example\r\n* Treatment-related AML (t-AML)\r\n** Patients must be previously untreated for secondary AML
To be eligible for the phase  efficacy phase:\r\n* Relapse patients:\r\n** Patients must be in first marrow relapse, and \r\n** Patients must not have received prior re-induction therapy; donor lymphocyte infusion (DLI) is considered a re-induction attempt
Meets ONE of the following disease criteria:\r\n* Primary (de novo) AML induction failure: no CR after  or more induction attempts with high dose chemotherapy (note: hypomethylating agents such as azacitidine will count as induction failure)\r\n* Relapsed AML or secondary AML (from myelodysplastic syndrome [MDS] or treatment related): not in CR after  or more cycles of standard re-induction therapy\r\n** For patients >  years of age the  cycle of standard chemotherapy is not required if either of the following criteria is met:\r\n*** Relapse within  months of last chemotherapy\r\n*** Bone marrow (BM) blast count < % within  days of starting protocol therapy\r\n* AML relapsed >  months after transplant: no re-induction required, and no more than  re-induction cycle is allowed\r\n* Use of hydroxyurea is permitted to control blasts counts\r\n* Patients with prior central nervous system (CNS) involvement are eligible provided that it has been treated and cerebrospinal fluid (CSF) is clear for at least  weeks prior to enrollment; CNS therapy (chemotherapy or radiation) should continue as medically indicated during the study treatment
In first relapse (with duration of remission of  months or less) or refractory after prior therapy, with or without HSCT. Induction therapy must have included at least  cycle of an anthracycline/mitoxantrone-containing induction block at a standard dose.
Subjects age ?  years with relapsed or refractory AML after ?  prior induction regimens, at least one containing anthracyclines
Patients must have been treated with - courses of therapy as first therapy for AML, commonly described as remission induction; examples include, but are not limited to:\r\n* Anthracycline containing regimens\r\n* Nucleoside analogs as monotherapy or in combination\r\n* Deoxyribonucleic acid (DNA) methyltransferase inhibitors
Patients must be in morphologic complete response (CR), complete response with incomplete hematologic recovery (CRi), partial response (PR) by international working group criteria post induction therapy, or patients refractory to induction therapy provided they have <  peripheral blasts/mm^ and white blood cells (WBC) =<  x ^/L; patients in PR and/or those who are refractory and who have undergone only one course of induction therapy will be eligible only if one or more of the following criteria are met:\r\n* Patient preference to forgo further induction therapy in favor of low or intermediate-intensity therapy\r\n* Patients are deemed unlikely to benefit from anthracycline cytarabine induction therapies for any of the following reasons:\r\n** Therapy-related AML\r\n** Prior myelodysplastic syndrome or myeloproliferative neoplasm\r\n** The presence of cytogenetic or molecular genetic features place patient in the Intermediate-I, Intermediate-II or adverse genetic group as defined by the European LeukemiaNet\r\n* Patients who have experienced one or more Common Terminology Criteria for Adverse Events (CTCAE) version (v). grade - treatment related non-hematologic toxicity within  days of beginning the first course of induction therapy
AML without complete remission (CR/CRc/CRi) after at least  induction therapies OR AML that has relapsed within  months after obtaining a CR OR AML that has relapsed more than  months after obtaining a CR, and has treatment failure (TF) or progressive disease (PD) following at least  re-induction regimen OR AML that has relapsed post-allogeneic transplantation
Patients must have primary refractory ALL based on failure to achieve a hematologic or molecular remission after induction therapy with dasatinib and steroids or dasatinib and chemotherapy, or have relapsed after treatment with a tyrosine kinase inhibitor with or without chemotherapy\r\n* Note: Prior course of dasatinib and steroid induction therapy should have included dasatinib mg PO daily on days - and prednisone mg/m^ (capped at mg, or equivalent steroid dose) on days -; if patients were unable to tolerate full steroid dose during induction therapy they will still be eligible\r\n* Note: Patients with refractory or relapsed disease in the central nervous system will be eligible
Failing to achieve a CR from original diagnosis after at least  induction attempt
Phase : i. Participants with AML who are refractory to, or have relapsed after, initial treatment for their disease, with no more than one prior line of therapy, and are judged not to be candidates for re-induction therapy that includes hematopoietic cell transplantation. Participants who have received prior cytarabine or decitabine are not excluded. OR ii. Participants with newly diagnosed, untreated AML ineligible for, or who have refused, standard intensive induction therapy
Patients must demonstrate one of the following:\r\n* Relapse after first complete remission\r\n* Refractory to induction chemotherapy (for example, failure to respond to  or more cycles of daunorubicin and cytarabine) or to reinduction\r\n* Refractory to hypomethylating agents
Primary AML induction failure: no complete remission (CR) after  or more induction attempts
Acute myeloid leukemia (AML) fitting within one of the following disease groups:\r\n* Primary induction failure (PIF): patients who have not achieved a complete remission (CR) after two induction cycles of cytotoxic therapy (i.e. +, mitoxantrone, etoposide, and cytarabine [MEC], fludarabine, cytarabine, and granulocyte-colony stimulating factor [FLAG], etc.) and having =< , absolute circulating blasts measured at least  days from prior therapy; hydroxyurea may be used to control blasts count; demethylating agents do not count as induction therapy; however early re-induction therapy based on residual disease on a day  bone marrow (BM) will count as a nd cycle\r\n* Relapsed disease with low disease burden: AML with =< , absolute circulating blasts; hydroxyurea may be used to control blasts count: no re-induction attempts are required, but a maximum of  re-induction attempts is allowed to be eligible\r\n* CR or greater: this will include CRp defined as CR without platelet recovery to ,/mcL\r\n* CR or CR with high risk features: includes therapy induced, prior myelodysplastic syndromes (MDS) or myeloproliferative disease (MPD), high risk cytogenetic or molecular phenotype with no available donor (sibling or unrelated adult)
Biphenotypic leukemia that at the time of allogeneic transplantation was in induction failure, relapsed disease, first, second or greater remission
Recipients with ALL in CR must have one of the following:\r\n* Adverse cytogenetics or residual disease detectable by flow cytometry, cytogenetic analysis, FISH, or PCR; adverse cytogenetics in ALL are defined as translocations involving t(;), t(;), t(;), q, t(;) or bcr-abl rearrangement or complex cytogenetic abnormalities\r\n* Primary induction failure, defined as failure to achieve CR with primary induction chemotherapy
Refractory B-ALL, defined by not having achieved a CR or CRi after two attempts at remission induction using standard regimens, or
Relapse after going into remission from re-induction for the first or subsequent relapse (ie: nd , rd, threlapse), OR
Refractory disease after first or greater relapse and a re-induction attempt, OR
Failing to go into remission from original diagnosis after  previous induction attempts.
Patients to be enrolled in the dose-escalation portion of this study must have T-cell ALL or T-cell lymphoblastic lymphoma (LL) in first relapse or must have failed primary induction chemotherapy (ie, never attained a complete remission following an initial course of standard therapy for T-ALL or T-LL). Patients to be enrolled in the cohort expansion portion of this study (ie, those treated at the recommended phase  dose) must have T-cell ALL in first relapse or must have failed primary induction chemotherapy (ie, never attained a complete remission following an initial course of standard therapy for T-ALL). T-LL patients are not eligible for the cohort expansion phase.
Anti-neoplastic treatment less than  days prior to enrollment, with the exceptions of hydroxyurea or, in the case of a patient with primary refractory AML, prior induction chemotherapy
A confirmed baseline diagnosis of AML by the revised guidelines of the International Working Group for AML including newly diagnosed, relapsed or refractory disease\r\n*Newly diagnosed: \r\n** Age  years and older \r\n** - years old and unfit for conventional chemotherapy\r\n* Relapsed disease: \r\n** Age  years and older any time following the first relapse, if the patient is not considered candidate for or is not interested in salvage chemotherapy\r\n** Age - years who have relapsed less than  months following achievement of a complete remission (defined as duration of remission from the time of documentation of complete morphologic remission to the time of documentation of relapse)\r\n* Refractory disease: \r\n** Age - years who have failed at least two lines of conventional chemotherapy (one induction and one salvage therapy); examples include: \r\n*** Patient achieves a complete remission and receives (or does not receive) consolidation therapy, but relapses later; this patient will be eligible only if s/he fails at least one salvage therapy following relapse\r\n*** Patient demonstrates residual leukemia on post-induction day  bone marrow and receives salvage therapy; this patient will be eligible only if s/he fails the salvage therapy\r\n*** Patient demonstrates reasonable response on post-induction day  bone marrow (or the bone marrow is not performed), but the follow-up bone marrow shows residual disease; this patient will be eligible only if s/he fails at least one salvage therapy\r\n** Age  and older who have failed at least one line of conventional chemotherapy, or treatment with hypomethylating agent (in the setting of poor-risk/complex karyotype) and is not considered candidate for or is not interested in salvage chemotherapy; FltITD +ve disease is not considered responsive to hypomethylating agent\r\n* Patients age  years and older with relapse in the form of AML after stem cell transplant will be eligible, even if they were transplanted for myelodysplastic syndromes (MDS) or myeloproliferative neoplasm (MPN)
Chemotherapy refractory acute leukemia (AL) will be defined by not in achieving a hematological remission after two consecutive standard courses of induction therapy
Part specific requirements: eligible to receive induction; achieved CR/CRi with standard induction and eligible to receive consolidation; in CR with documented blood count recovery for maintenance
AML relapsed or refractory to at least one attempt at induction or subjects not candidates for aggressive induction regimens
Participants with Hodgkin or Non-Hodgkin lymphoma must meet one of the following criteria:\r\n* Relapsing disease in nd or greater relapse and measurable disease, or\r\n* Refractory disease failing to achieve complete response (CR) with >=  induction or re-induction attempts
Patients with AML must have had at least  prior therapeutic attempts including frontline induction.
Subjects who are refractory* or who have relapsed** following first line AML therapy with cytarabine/anthracycline based chemotherapy, with or without a tyrosine kinase inhibitor. *Refractory to induction therapy is defined as never achieving CR, CRi or CRp (according to International Working Group criteria) after one line of intensive regimen for AML (re-induction, consolidation and/or transplant allowed) including at least one cytarabine containing induction block with a total dose no less than mg/m per cycle and  days of an anthracycline with or without a TKI. or **First relapse is defined as untreated hematologic relapse (according to International Working Group criteria) after one line of intensive regimen for AML (re-induction, consolidation and/or transplant allowed) including at least one cytarabine containing induction block with a total dose no less than mg/m per cycle and  days of an anthracycline with or without a TKI that induced a CR/CRi/CRp. Subjects are allowed to receive induction, consolidation, transplant and/or maintenance prior to achieving their first CR/CRi/CRp.
Patients with relapsed or refractory AML; patients must have failed at least one prior induction regimen for AML; the maximum number of prior lines of induction is 
Either achieved complete remission (greater than  weeks in duration) with initial induction/consolidation and have experienced relapse of disease or declined treatment with high-dose induction/consolidation
Patients with WHO-defined AML,  years of age or older, who are unlikely to benefit from standard induction therapy, defined as having at least  of the following:
Patients may be registered for consolidation provided that they were eligible for the initial induction/re-induction registration and satisfy the following additional criteria:\r\n* Patients must have achieved morphologic remission (complete remission [CR] or complete remission with incomplete blood count recover [CRi]) after completion of induction or re-induction therapy; patient must remain in remission until beginning consolidation and this must be documented by bone marrow and peripheral blood examination within  days prior to registration to Step \r\n* All non-hematologic treatment related toxicities that are deemed clinically significant by the treating physician must have resolved to =< grade \r\n* Patients must not have received allogeneic stem cell transplant
The patient has adverse risk disease or AML for which there is otherwise a substantial risk of relapse, which includes but is not limited to: adverse karyotype, FLT internal tandem duplication (ITD) mutation, history of antecedent hematologic disorder (AHD), therapy-related AML, history of requiring more than  cycle of intensive induction chemotherapy to achieve first remission, and/or presence of persistent MRD (detected by cytogenetics, molecular markers, or flow cytometry) at any point after the initial induction cycle.
Patient must be either primary refractory to one frontline induction therapy or relapsed after one frontline induction therapy; patients who do not achieve complete remission after induction therapy are also eligible
Refractory disease is defined by the failure to obtain a complete remission (CR) with a HDAC-containing or a standard induction regimen. Patients who require two cycles of induction therapy to attain a first CR are not considered to have refractory disease.
Refractory patients:\r\n* Patients must have received at least two attempts at remission induction, which may consist of up to two different therapy courses; Children's Oncology Group (COG) AAML de novo therapy including induction I and induction II is one remission attempt
Patients with multiple myeloma who have not achieved a complete remission (CR) following at least  cycles of induction therapy
MDS  may have achieved CR through either hypomethylating agent therapy, induction chemotherapy, or other therapy